 |
|
|
| |
MK-8408, a Potent and Selective NS5A Inhibitor With a High Genetic Barrier to Resistance and Activity Against HCV Genotypes 1-6
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Ernest Asante-Appiah1, Rong Liu1, Stephanie Curry1, Patricia McMonagle1, Sony Agrawal2, Donna Carr2, Laura Rokosz2, Fred Lahser1,Karin Bystol1, Robert Chase1, Stuart Black1, Eric Ferrari1, Paul Ingravallo1, Shiying Chen3, Ling Tong4, Wensheng Yu4, and Joseph Kozlowski4
1Departments of Infectious Diseases, 2In Vitro Pharmacology, 3Preclinical Pharmacokinetics & Drug Metabolism, and 4Medicinal Chemistry, Merck & Co., Inc., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
